Transforming the Discovery of Novel GPCR-Targeted Therapies

With positive clinical read outs by Tectonic Therapeutics and recent funding rounds for Confo Therapeutics and Septerna, the potential for novel GPCR drug classes to treat a plethora of diseases grows. Now more than ever, there is a need for the community to come together to share scientific advancements and collaboration opportunities across the full spectrum of GPCR drugs, from small molecules to therapeutic proteins and antibodies.

The 4th GPCRs-Targeted Drug Discovery Summit is returning to Boston to showcase the hottest targets of interest, mechanism of action of new GPCR ligands, cutting-edge computational tools to identify high-potential candidates, and effective translational strategies to drive forward discovery and development pipelines to patients in need.

URLs:

Tickets: https://go.evvnt.com/2886576-1?pid=91 

Brochure: https://go.evvnt.com/2886576-2?pid=91 

Prices:

Drug Developer Price - Conference Only: USD 2999.00,

Drug Developer Price - Conference + Focus Day: USD 4896.00,

Academics Price - Conference Only: USD 2599.00,

Academics Price - Conference + Focus Day: USD 4196.00,

Solution + Service Providers - Conference Only: USD 3699.00,

Solution + Service Providers - Conference + Focus Day: USD 5297.00

Speakers: Alpay Seven Senior Principal Scientist and Head of Structural Biology Deep Apple Therapeutics, Cesare Orlandi Assistant Professor University of Rochester Medical Center, David Minh Chief Scientific Officer Biagon Inc, David O'Connell Associate Professor University College Dublin, Dipak Patil Senior Advisor and Structural Biologist Eli Lilly and Co., Eswar Iyer Chief Executive Officer Aikium, Gary Jacob, Ph.D. Chief Executive Officer OKYO Pharma Ltd., Glenn Short Chief Scientific Officer ATAI Life Sciences, Hariprasad Vankayalapati Chief Scientific Officer Biolexis Therapeutics, Jean-Philippe Fortin Senior Director and Head of Scientific Pharmacology Internal Medicine Research Unit Pfizer, Laetitia Comps-Agrar Senior Principal Scientist - Biochemical and Cellular Pharmacology Genentech, Laurent Sabbagh Scientific Director Biology Domain Therapeutics, Pieter Claes Principal Scientist - Medicinal Chemistry Confo Therapeutics, Richard Yu Co-Founder and Chief Executive Officer Abalone Bio, Stacey Southall Vice President and Head of Platform Technology Nxera Pharma, Stephan Schann Chief Scientific Officer Domain Therapeutics, Xianqiang Song Director of Structural Biology Technology Platform Structure Therapeutics, Ximena Barros Alvarez Senior Scientist - Membrane Protein Biochemistry Tectonic Therapeutics